649 related articles for article (PubMed ID: 22740503)
1. Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21.
Iglesias P; Selgas R; Romero S; Díez JJ
Eur J Endocrinol; 2012 Sep; 167(3):301-9. PubMed ID: 22740503
[TBL] [Abstract][Full Text] [Related]
2. Dynamic change of serum FGF21 levels in response to glucose challenge in human.
Lin Z; Gong Q; Wu C; Yu J; Lu T; Pan X; Lin S; Li X
J Clin Endocrinol Metab; 2012 Jul; 97(7):E1224-8. PubMed ID: 22539584
[TBL] [Abstract][Full Text] [Related]
3. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives.
Woo YC; Xu A; Wang Y; Lam KS
Clin Endocrinol (Oxf); 2013 Apr; 78(4):489-96. PubMed ID: 23134073
[TBL] [Abstract][Full Text] [Related]
4. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models--association with liver and adipose tissue effects.
Xu J; Stanislaus S; Chinookoswong N; Lau YY; Hager T; Patel J; Ge H; Weiszmann J; Lu SC; Graham M; Busby J; Hecht R; Li YS; Li Y; Lindberg R; Véniant MM
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1105-14. PubMed ID: 19706786
[TBL] [Abstract][Full Text] [Related]
5. Serum fibroblast growth factor 21 is associated with adverse lipid profiles and gamma-glutamyltransferase but not insulin sensitivity in Chinese subjects.
Li H; Bao Y; Xu A; Pan X; Lu J; Wu H; Lu H; Xiang K; Jia W
J Clin Endocrinol Metab; 2009 Jun; 94(6):2151-6. PubMed ID: 19318452
[TBL] [Abstract][Full Text] [Related]
6. Serum fibroblast growth factor 21 in human obesity: regulation by insulin infusion and relationship with glucose and lipid oxidation.
Strączkowski M; Karczewska-Kupczewska M; Adamska A; Otziomek E; Kowalska I; Nikołajuk A
Int J Obes (Lond); 2013 Oct; 37(10):1386-90. PubMed ID: 23419601
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor 21 improves insulin resistance and ameliorates renal injury in db/db mice.
Kim HW; Lee JE; Cha JJ; Hyun YY; Kim JE; Lee MH; Song HK; Nam DH; Han JY; Han SY; Han KH; Kang YS; Cha DR
Endocrinology; 2013 Sep; 154(9):3366-76. PubMed ID: 23825123
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice.
Xu J; Lloyd DJ; Hale C; Stanislaus S; Chen M; Sivits G; Vonderfecht S; Hecht R; Li YS; Lindberg RA; Chen JL; Jung DY; Zhang Z; Ko HJ; Kim JK; Véniant MM
Diabetes; 2009 Jan; 58(1):250-9. PubMed ID: 18840786
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological efficacy of FGF21 analogue, liraglutide and insulin glargine in treatment of type 2 diabetes.
Ye X; Qi J; Yu D; Wu Y; Zhu S; Li S; Wu Q; Ren G; Li D
J Diabetes Complications; 2017 Apr; 31(4):726-734. PubMed ID: 28143735
[TBL] [Abstract][Full Text] [Related]
10. FGF21 Normalizes Plasma Glucose in Mouse Models of Type 1 Diabetes and Insulin Receptor Dysfunction.
Diener JL; Mowbray S; Huang WJ; Yowe D; Xu J; Caplan S; Misra A; Kapur A; Shapiro J; Ke X; Wu X; Bose A; Panza D; Chen M; Beaulieu V; Gao J
Endocrinology; 2021 Sep; 162(9):. PubMed ID: 33951176
[TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor-21, energy balance and obesity.
Giralt M; Gavaldà-Navarro A; Villarroya F
Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():66-73. PubMed ID: 26415590
[TBL] [Abstract][Full Text] [Related]
12. Daily physical activity, fasting glucose, uric acid, and body mass index are independent factors associated with serum fibroblast growth factor 21 levels.
Cuevas-Ramos D; Almeda-Valdes P; Gómez-Pérez FJ; Meza-Arana CE; Cruz-Bautista I; Arellano-Campos O; Navarrete-López M; Aguilar-Salinas CA
Eur J Endocrinol; 2010 Sep; 163(3):469-77. PubMed ID: 20566587
[TBL] [Abstract][Full Text] [Related]
13. Naringenin prevents obesity, hepatic steatosis, and glucose intolerance in male mice independent of fibroblast growth factor 21.
Assini JM; Mulvihill EE; Burke AC; Sutherland BG; Telford DE; Chhoker SS; Sawyez CG; Drangova M; Adams AC; Kharitonenkov A; Pin CL; Huff MW
Endocrinology; 2015 Jun; 156(6):2087-102. PubMed ID: 25774553
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor 21: effects on carbohydrate and lipid metabolism in health and disease.
Kralisch S; Fasshauer M
Curr Opin Clin Nutr Metab Care; 2011 Jul; 14(4):354-9. PubMed ID: 21505329
[TBL] [Abstract][Full Text] [Related]
15. Postprandial changes in glucose oxidation and insulin sensitivity in metabolic syndrome: Influence of fibroblast growth factor 21 and vitamin D status.
Pathak K; Soares MJ; Zhao Y; James AP; Sherriff JL; Newsholme P
Nutrition; 2017 May; 37():37-42. PubMed ID: 28359360
[TBL] [Abstract][Full Text] [Related]
16. Lack of overt FGF21 resistance in two mouse models of obesity and insulin resistance.
Hale C; Chen MM; Stanislaus S; Chinookoswong N; Hager T; Wang M; Véniant MM; Xu J
Endocrinology; 2012 Jan; 153(1):69-80. PubMed ID: 22067317
[TBL] [Abstract][Full Text] [Related]
17. Adiponectin mediates the metabolic effects of FGF21 on glucose homeostasis and insulin sensitivity in mice.
Lin Z; Tian H; Lam KS; Lin S; Hoo RC; Konishi M; Itoh N; Wang Y; Bornstein SR; Xu A; Li X
Cell Metab; 2013 May; 17(5):779-89. PubMed ID: 23663741
[TBL] [Abstract][Full Text] [Related]
18. Association between insulin resistance and impairment of FGF21 signal transduction in skeletal muscles.
Jeon JY; Choi SE; Ha ES; Kim TH; Jung JG; Han SJ; Kim HJ; Kim DJ; Kang Y; Lee KW
Endocrine; 2016 Jul; 53(1):97-106. PubMed ID: 26758997
[TBL] [Abstract][Full Text] [Related]
19. The FGF21 response to fructose predicts metabolic health and persists after bariatric surgery in obese humans.
Ter Horst KW; Gilijamse PW; Demirkiran A; van Wagensveld BA; Ackermans MT; Verheij J; Romijn JA; Nieuwdorp M; Maratos-Flier E; Herman MA; Serlie MJ
Mol Metab; 2017 Nov; 6(11):1493-1502. PubMed ID: 29107295
[TBL] [Abstract][Full Text] [Related]
20. Effects of insulin and exercise training on FGF21, its receptors and target genes in obesity and type 2 diabetes.
Kruse R; Vienberg SG; Vind BF; Andersen B; Højlund K
Diabetologia; 2017 Oct; 60(10):2042-2051. PubMed ID: 28721439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
